Loading...
ROCO
4131
Market cap40mUSD
Nov 13, Last price  
32.30TWD
Name

DR.Chip Biotechnology Inc

Chart & Performance

D1W1MN
ROCO:4131 chart
P/E
P/S
20.47
EPS
Div Yield, %
Shrs. gr., 5y
15.47%
Rev. gr., 5y
-10.05%
Revenues
62m
-4.92%
104,489,00093,345,00088,926,00088,968,00064,729,00061,545,000
Net income
-48m
L-25.54%
-11,865,000-27,096,000-17,197,000-28,215,000-64,645,000-48,137,000
CFO
-57m
L-10.53%
-4,334,000-27,769,000-17,154,000-2,689,000-63,883,000-57,154,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NeoCore Technology Co., Ltd. designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices. The company's products include food safety examination systems, human diagnosis arrays systems, agriculture examination systems, food examination arrays systems, and laboratory instruments, as well as DNA kits. It also offers laboratory planning, design, and other services. In addition, the company engages in the wholesale and retail of contact lenses. The company was formerly known as DR. Chip Biotechnology Incorporation and changed its name to NeoCore Technology Co., Ltd. in July 2023. NeoCore Technology Co., Ltd. was founded in 1987 and is headquartered in Tainan, Taiwan.
IPO date
Mar 12, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT